Clinical trialNo phase (not a drug trial)Completed
EUS-RFA for Unresectable Pancreatic Cancer
Efficacy and Safety of Endoscopic Ultrasonography-guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 1 March 2020
- Ended
- 25 August 2021
- Enrollment
- 8 participants
- Sites
- 1
- Primary outcomes
- Tumor size
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 30 August 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.
Detailed description public domain (ClinicalTrials.gov)
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.